INTRODUCTION
The estimation of Hepatitis C virus (HCV) -infected individuals in Turkey is between 400,000 and 800,000 and approximately more than three-fourth of all infected individuals are unaware of their infection (1) . HCV is primarily transmitted through percutaneous exposure to blood and blood products, mother-to-infant, contaminated devices shared with drug uses and sexual transmission (2) (3) (4) (5) . HCV is not spread by hugging, holding hands, sneezing, coughing, or sharing eating materials or drinking glasses. HCV is not transmitted through water or food.
All individuals recommended for HCV testing should first be tested for HCV antibody (anti-HCV). A positive test result indicates active HCV infection (acute or chronic), past infection or a false-positive test result. HCV RNA testing is necessary to confirm active (current) infection.
I. GROUPS THAT NEED TO BE PRIORITIZED FOR CHRONIC HEPATITIS C VIRUS ASSESSMENT I.A. High-Risk Behaviors
• Drug-injection and substance use • Non-Intravenous (IV) drug addicts • People with history of risky sexual behavior i. Men who have unprotected sex with men ii. People with multiple partners iii. Sex workers
I.B. High-Risk Exposures
• Long-term hemodialysis patients • Occupational groups (healthcare, emergency medical, hairdressers, beauty salon workers, etc.) • Children born to HCV-infected women • People with percutaneous/parenteral exposures in an unregulated setting (tattoos and piercings, group circumcisions, manicure or pedicure performed under unhygienic conditions)
SUMMARY
The present guideline updates the Turkish recommendations for the screening, diagnosis and management of Hepatitis C virus (HCV) infection prepared by the Turkish Association for the Study of the Liver (TASL) and Viral Hepatitis Society (VHS). The aim of this guidance was to provide updates recommendations to physicians, who are interested in HCV care on the optimal screening, diagnosis and pre-treatment management for patients with HCV infection in Turkey. These recommendations, produced by panel experts, were aimed to addresses the management issues ranging from diagnosis and linkage to care, to the optimal treatment regimen in patients with HCV infection. Recommendations are based on evidence and opinions of more than 70% of the panelists. This guidance is supported by the memberships of two societies and not by pharmaceutical companies. This guidance will be updated frequently as new data become available.
• People with a history of shared use of "personal hygienic items", • People with a history of dental procedures and medical interventions, 
III. LABORATORY AND RADIOLOGICAL TOOLS TO BE USED IN DIAGNOSIS

III.A. General Laboratory Tests
Biochemical tests: Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), alkaline phosphatase (ALP), albumin and total bilirubin levels.
It is important to demonstrate liver damage by biochemical tests for diagnosis. Elevation of serum transaminases is generally in correlation with inflammation and fibrosis; however, normal serum aminotransferases levels do not rule out liver damage.
Hematological tests:
Complete blood count (CBC), international normalized ration (INR) level.
III. B. Serological Tests Anti-HCV:
Anti-HCV should be used as a screening test. Third or fourth generation "enzyme immunoassay (EIA) tests" need to be used. This test can be negative during the 3-4 weeks following the acquisition of the virus or in immunosuppressed individuals. Anti-HCV positivity continues after spontaneous or treatment-induced viral clearance. However, in some it might be disappeared. 
Other serological tests:
III. D. Radiological Tests Abdominal ultrasound, computed tomography (CT) scan and magnetic resonance imaging (MRI)
can assess liver surface nodularity, liver and spleen size and the presence of portal hypertension
III.E. Identification of Fibrosis Stage
• The severity of liver disease is a key factor in determining the initial and subsequent evaluation of patients with HCV infection. A liver biopsy can provide objective information regarding severity of hepatic necroinflammation and fibrosis, and help exclude competing causes of liver injury. However, sampling error and observer variability limit its performance.
• Noninvasive methods include indirect and direct serum biomarkers (Fibrotest, APRI, FIB-4, etc.), transient elastography (MR elastography, fibroscan) used to estimate the degree of fibrosis. No single test is recognized to have high accuracy alone. The most efficient approach to degree of fibrosis assessment is to combine direct serum markers and transient liver elastography (8-9).
• A liver biopsy is not necessary to identify the stage of fibrosis in patients diagnosed clinical cirrhosis.
IV. DIAGNOSIS OF ACUTE HEPATITIS C IV.A.
Acute HCV infection may result from exposure to the virus through varies routes as described above. Approximately, 20-50% of patients with acute HCV infection have spontaneous resolution of the infection (2-6). Anti-HCV antibody and HCV RNA testing are recommended when acute HCV infection is due to exposure (2-6). 
IV.B.
A diagnosis of acute hepatitis C can be made when HCV RNA test is detectable in patients with a presentation of acute hepatitis (serum ALT level>10 times upper limit of normal and jaundice), who had previously a negative anti-HCV test (2-6).
The other causes of acute hepatitis should be excluded in patients suspected acute HCV infection.
V. DIAGNOSIS OF CHRONIC HEPATITIS C
The diagnosis of chronic hepatitis C (CHC) is defined as positive anti-HCV and HCV RNA testing for at least 6 months in patients with HCV infection (2-6). In some cases, there might be HCV RNA positivity by itself. Before the treatment, the severity of the disease is identified with invasive or non-invasive methods.
VI. TREATMENT INDICATIONS FOR CHC INFECTION
• The goal of antiviral treatment for HCV infection is to reduce liver-related morbidity and mortality by the achievement of virological cure. (2-6) • Antiviral therapy is recommended for all CHC patients with positive anti HCV and HCV RNA testing, except those with a short life expectancy (less than one year). In Turkey, antiviral therapy is currently reimbursed for CHC patients with ≥F1 fibrosis (Ishak score).
• Decompensated patients should be managed by expert physician in liver transplantation (LT) unit. If MELD score is >20, LT should be planned and antiviral treatment should be postponed to the period after LT. However, if the transplantation waiting period is more than 6 months, antiviral treatment should be started before LT.
VII. TREATMENT RESPONSE DEFINITIONS Sustained virological response (SVR):
Sustained virological response (SVR) is defined as the continued absence of detectable serum HCV RNA levels at 12 and 24 weeks after completion of therapy. SVR is a marker for cure of HCV infection. Virological cure decreases in liver inflammation, reduces in rate of disease progression, improves portal hypertension and other clinical manifestations of advanced liver disease, reduces in the risk of hepatocellular carcinoma (HCC) and substantially improves quality of life. These reductions contribute to ultimately reductions in all-cause mortality. Therefore, CHC patients should be treated, preferably early in the course of disease before the development of severe liver disease and its complications.
Permanent virological response:
SVR has been shown to persist in more than 99% of CHC patients followed more than 5 years
Relapse: Relapse is defined as undetectable serum HCV RNA at end of the antiviral treatment followed by a detectable HCV RNA after antiviral treatment discontinuation
VIII. PRE-TREATMENT EVALUATION
Pre-treatment evaluation should be made in all patients. CHC patients should receive education about interventions aimed his/her disease course and preventing HCV transmission. Patients should also be educated about the crucial importance of adherence to drugs, and the necessity for close supervision and laboratory tests during and after antiviral treatment. (2) (3) (4) (5) (6) The following points should be covered in detail (2-6):
• Serum pregnancy testing is recommended for women of childbearing age prior to antiviral therapy that includes ribavirin.
• Vaccination against hepatitis A and B is recommended for all susceptible patients.
• Vaccination against pneumococcal infection is recommended to all cirrhotic patients.
• Screening for HCC is necessary in all cirrhotic patients.
• Staging of hepatic fibrosis is essential prior to antiviral therapy for facilitating an appropriate decision about HCV treatment strategy. Liver disease severity using the Child-Turcotte-Pugh (CTP) score should be assessed. • If HCV RNA is positive at 4 th week of the treatment, repeat HCV RNA testing is recommended at 6 th week of the treatment. If HCV viral load has increased by >1 log 10 IU/mL, discontinuation of treatment is recommended.
X. FOLLOW-UP AFTER TREATMENT IN PATIENTS HAVING SVR
• HCV viral load testing can be considered at 24 weeks or longer following the completion therapy.
• For non-cirrhotic patients, if HCV RNA is negative at 48 weeks after treatment, the follow-up can be discontinued.
• In patients with cirrhosis/severe fibrosis (metavir 3-4, Ishak ≥4) follow-up for HCC should be continued with ultrasonography and alpha-fetoprotein (AFP).
• In patients with an ongoing HCV transmission risk, HCV RNA should be tested once a year.
• HCV recurrence controls are not made in patients who are receiving chemo/immunosuppressive treatment or chemotherapy.
XI. FOLLOW-UP AFTER TREATMENT FOR PATIENTS WHO DO NOT HAVE SVR
• Should be evaluated for new treatments.
• HCC surveillance should be continued with abdominal ultrasonography and AFP every 6 months in patients with cirrhosis/severe fibrosis.
• Cirrhotic patients should be followed-up. Endoscopic examinations for portal hypertension are same in other cirrhotic patients.
• Non-cirrhotic patients are followed-up by CBC, biochemistry and INR test every 6 months.
